Cargando…
Dual time point (18)F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging ((18)F-FDG PET/CT) in primary breast cancer
BACKGROUND: To evaluate the clinicopathological and prognostic significance of the percentage change between maximum standardized uptake value (SUV(max)) at 60 min (SUV(max)1) and SUV(max) at 120 min (SUV(max)2) (ΔSUV(max)%) using dual time point (18)F-fluorodeoxyglucose emission tomography/computed...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6882358/ https://www.ncbi.nlm.nih.gov/pubmed/31775675 http://dx.doi.org/10.1186/s12885-019-6315-8 |
_version_ | 1783474142949933056 |
---|---|
author | YAMAGISHI, Yoji KOIWAI, Tomomi YAMASAKI, Tamio EINAMA, Takahiro FUKUMURA, Makiko HIRATSUKA, Miyuki KONO, Takako HAYASHI, Katsumi ISHIDA, Jiro UENO, Hideki TSUDA, Hitoshi |
author_facet | YAMAGISHI, Yoji KOIWAI, Tomomi YAMASAKI, Tamio EINAMA, Takahiro FUKUMURA, Makiko HIRATSUKA, Miyuki KONO, Takako HAYASHI, Katsumi ISHIDA, Jiro UENO, Hideki TSUDA, Hitoshi |
author_sort | YAMAGISHI, Yoji |
collection | PubMed |
description | BACKGROUND: To evaluate the clinicopathological and prognostic significance of the percentage change between maximum standardized uptake value (SUV(max)) at 60 min (SUV(max)1) and SUV(max) at 120 min (SUV(max)2) (ΔSUV(max)%) using dual time point (18)F-fluorodeoxyglucose emission tomography/computed tomography ((18)F-FDG PET/CT) in breast cancer. METHODS: Four hundred and sixty-four patients with primary breast cancer underwent (18)F-FDG PET/CT for preoperative staging. ΔSUV(max)% was defined as (SUV(max)2 − SUV(max)1) / SUV(max)1 × 100. We explored the optimal cutoff value of SUV(max) parameters (SUV(max)1 and ΔSUV(max)%) referring to the event of relapse by using receiver operator characteristic curves. The clinicopathological and prognostic significances of the SUV(max)1 and ΔSUV(max)% were analyzed by Cox’s univariate and multivariate analyses. RESULTS: The optimal cutoff values of SUV(max)1 and ΔSUV(max)% were 3.4 and 12.5, respectively. Relapse-free survival (RFS) curves were significantly different between high and low SUV(max)1 groups (P = 0.0003) and also between high and low ΔSUV(max)% groups (P = 0.0151). In Cox multivariate analysis for RFS, SUV(max)1 was an independent prognostic factor (P = 0.0267) but ΔSUV(max)% was not (P = 0.152). There was a weak correlation between SUV(max)1 and ΔSUV(max)% (P < 0.0001, R(2) = 0.166). On combining SUV(max)1 and ΔSUV(max)%, the subgroups of high SUV(max)1 and high ΔSUV(max)% showed significantly worse prognosis than the other groups in terms of RFS (P = 0.0002). CONCLUSION: Dual time point (18)F-FDG PET/CT evaluation can be a useful method for predicting relapse in patients with breast cancer. The combination of SUV(max)1 and ΔSUV(max)% was able to identify subgroups with worse prognosis more accurately than SUV(max)1 alone. |
format | Online Article Text |
id | pubmed-6882358 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-68823582019-12-03 Dual time point (18)F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging ((18)F-FDG PET/CT) in primary breast cancer YAMAGISHI, Yoji KOIWAI, Tomomi YAMASAKI, Tamio EINAMA, Takahiro FUKUMURA, Makiko HIRATSUKA, Miyuki KONO, Takako HAYASHI, Katsumi ISHIDA, Jiro UENO, Hideki TSUDA, Hitoshi BMC Cancer Research Article BACKGROUND: To evaluate the clinicopathological and prognostic significance of the percentage change between maximum standardized uptake value (SUV(max)) at 60 min (SUV(max)1) and SUV(max) at 120 min (SUV(max)2) (ΔSUV(max)%) using dual time point (18)F-fluorodeoxyglucose emission tomography/computed tomography ((18)F-FDG PET/CT) in breast cancer. METHODS: Four hundred and sixty-four patients with primary breast cancer underwent (18)F-FDG PET/CT for preoperative staging. ΔSUV(max)% was defined as (SUV(max)2 − SUV(max)1) / SUV(max)1 × 100. We explored the optimal cutoff value of SUV(max) parameters (SUV(max)1 and ΔSUV(max)%) referring to the event of relapse by using receiver operator characteristic curves. The clinicopathological and prognostic significances of the SUV(max)1 and ΔSUV(max)% were analyzed by Cox’s univariate and multivariate analyses. RESULTS: The optimal cutoff values of SUV(max)1 and ΔSUV(max)% were 3.4 and 12.5, respectively. Relapse-free survival (RFS) curves were significantly different between high and low SUV(max)1 groups (P = 0.0003) and also between high and low ΔSUV(max)% groups (P = 0.0151). In Cox multivariate analysis for RFS, SUV(max)1 was an independent prognostic factor (P = 0.0267) but ΔSUV(max)% was not (P = 0.152). There was a weak correlation between SUV(max)1 and ΔSUV(max)% (P < 0.0001, R(2) = 0.166). On combining SUV(max)1 and ΔSUV(max)%, the subgroups of high SUV(max)1 and high ΔSUV(max)% showed significantly worse prognosis than the other groups in terms of RFS (P = 0.0002). CONCLUSION: Dual time point (18)F-FDG PET/CT evaluation can be a useful method for predicting relapse in patients with breast cancer. The combination of SUV(max)1 and ΔSUV(max)% was able to identify subgroups with worse prognosis more accurately than SUV(max)1 alone. BioMed Central 2019-11-27 /pmc/articles/PMC6882358/ /pubmed/31775675 http://dx.doi.org/10.1186/s12885-019-6315-8 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article YAMAGISHI, Yoji KOIWAI, Tomomi YAMASAKI, Tamio EINAMA, Takahiro FUKUMURA, Makiko HIRATSUKA, Miyuki KONO, Takako HAYASHI, Katsumi ISHIDA, Jiro UENO, Hideki TSUDA, Hitoshi Dual time point (18)F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging ((18)F-FDG PET/CT) in primary breast cancer |
title | Dual time point (18)F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging ((18)F-FDG PET/CT) in primary breast cancer |
title_full | Dual time point (18)F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging ((18)F-FDG PET/CT) in primary breast cancer |
title_fullStr | Dual time point (18)F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging ((18)F-FDG PET/CT) in primary breast cancer |
title_full_unstemmed | Dual time point (18)F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging ((18)F-FDG PET/CT) in primary breast cancer |
title_short | Dual time point (18)F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging ((18)F-FDG PET/CT) in primary breast cancer |
title_sort | dual time point (18)f-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging ((18)f-fdg pet/ct) in primary breast cancer |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6882358/ https://www.ncbi.nlm.nih.gov/pubmed/31775675 http://dx.doi.org/10.1186/s12885-019-6315-8 |
work_keys_str_mv | AT yamagishiyoji dualtimepoint18ffluorodeoxyglucosepositronemissiontomographycomputedtomographyfusionimaging18ffdgpetctinprimarybreastcancer AT koiwaitomomi dualtimepoint18ffluorodeoxyglucosepositronemissiontomographycomputedtomographyfusionimaging18ffdgpetctinprimarybreastcancer AT yamasakitamio dualtimepoint18ffluorodeoxyglucosepositronemissiontomographycomputedtomographyfusionimaging18ffdgpetctinprimarybreastcancer AT einamatakahiro dualtimepoint18ffluorodeoxyglucosepositronemissiontomographycomputedtomographyfusionimaging18ffdgpetctinprimarybreastcancer AT fukumuramakiko dualtimepoint18ffluorodeoxyglucosepositronemissiontomographycomputedtomographyfusionimaging18ffdgpetctinprimarybreastcancer AT hiratsukamiyuki dualtimepoint18ffluorodeoxyglucosepositronemissiontomographycomputedtomographyfusionimaging18ffdgpetctinprimarybreastcancer AT konotakako dualtimepoint18ffluorodeoxyglucosepositronemissiontomographycomputedtomographyfusionimaging18ffdgpetctinprimarybreastcancer AT hayashikatsumi dualtimepoint18ffluorodeoxyglucosepositronemissiontomographycomputedtomographyfusionimaging18ffdgpetctinprimarybreastcancer AT ishidajiro dualtimepoint18ffluorodeoxyglucosepositronemissiontomographycomputedtomographyfusionimaging18ffdgpetctinprimarybreastcancer AT uenohideki dualtimepoint18ffluorodeoxyglucosepositronemissiontomographycomputedtomographyfusionimaging18ffdgpetctinprimarybreastcancer AT tsudahitoshi dualtimepoint18ffluorodeoxyglucosepositronemissiontomographycomputedtomographyfusionimaging18ffdgpetctinprimarybreastcancer |